MAPT and Alzheimer disease: The TREM2 pathway can be targeted by specific antibodies or small molecules that regulate downstream signaling.211 AL002, an monoclonal antibody of TREM2, has undergone Phase II clinical trial for the treatment of early AD.536 In an AD mouse model, administration of AL002c, a variant of the AL002 antibody, attenuated tau plaques and neurite dystrophy, improved behavior, and reduced microglial inflammation.537 Other drugs targeting TREM2, including DNL919 and AL044, are also undergoing clinical trials (clinicaltrials.gov).